News Headlines Article

Generic-drug delays blamed for high costs
Sacramento Bee

Californians with cancer, heart disease, epilepsy and other conditions have been forced to pay an average of 10 times more than necessary for at least 20 key drugs, according to a report by the California Public Interest Research Group and Boston-based Community Catalyst. The report, titled “Top Twenty Pay-for-Delay Drugs: How Drug Industry Payoffs Delay Generics, Inflate Prices and Hurt Consumers,” claims the affected drugs have been subject to an industry practice called “pay for delay,” in which brand-name pharmaceutical companies pay off generic drug manufacturers to keep lower-cost equivalents off the market.